利伐沙班与华法林在无诱因静脉血栓栓塞症患者中的有效性和安全性:一项倾向匹配的全国队列研究
该研究基于丹麦全国健康登记数据,纳入无诱因静脉血栓栓塞症(VTE)首次住院且新使用利伐沙班或华法林的患者,经倾向匹配后比较6个月随访期间复发性VTE和大出血发生率。利伐沙班组复发性VTE发生率为9.9例/100人年,华法林组为13.1例/100人年(HR 0.74,95%CI 0.56-0.96);大出血发生率分别为2.4例/100人年与2.0例/100人年(HR 1.19,95%CI 0.66-2.13)。作者认为在临床实践环境中,利伐沙班与复发性VTE风险降低相关且未损害安全性。
要点
- 利伐沙班组6个月复发性VTE发生率为9.9例/100人年,华法林组为13.1例/100人年(HR 0.74,95%CI 0.56-0.96)。
- 利伐沙班组6个月大出血发生率为2.4例/100人年,华法林组为2.0例/100人年(HR 1.19,95%CI 0.66-2.13)。
- 作者认为在临床实践环境中,利伐沙班与复发性VTE风险降低相关且未损害安全性。
核心结论
- 在临床实践环境中,无诱因VTE患者使用利伐沙班与标准治疗相比,复发性VTE风险降低且未损害安全性。
研究设计与样本
- 倾向匹配队列研究,链接丹麦全国健康登记数据,识别首次住院诊断为无诱因VTE且新使用利伐沙班或华法林的患者。
- 排除标准包括:VTE诊断前未在丹麦居住至少1年、仅有门诊VTE诊断、有其他口服抗凝适应证、既往使用过口服抗凝药、VTE后7天内无利伐沙班或华法林处方、同时领取利伐沙班和华法林或其他口服抗凝药处方。
- 2011年12月9日至2016年2月28日期间识别29963例新发VTE患者,排除后经倾向匹配得到利伐沙班组1734例(匹配前1751例)和华法林组2945例。
- 主要有效性结局为复发性VTE,主要安全性结局为大出血;采用倾向匹配和Cox回归比较两组结局发生率。
主要发现
- 6个月随访时,利伐沙班组复发性VTE发生率为9.9例/100人年,华法林组为13.1例/100人年,HR 0.74(95%CI 0.56-0.96)。
- 6个月随访时,利伐沙班组大出血发生率为2.4例/100人年,华法林组为2.0例/100人年,HR 1.19(95%CI 0.66-2.13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as venous thromboembolism (VTE), which is a common vascular disease and a major cause of morbidity and mortality worldwide. We compare effectiveness and safety of rivaroxaban versus warfarin in a prospective cohort of routine care patients with incident unprovoked VTE. METHODS: In this propensity-matched cohort study, we linked nationwide Danish health registries to identify all patients with a first hospital diagnosis of unprovoked VTE who were new users of rivaroxaban or warfarin. Excluded patients included those who had not been residents in Denmark for at least 1 year before VTE diagnosis, patients with outpatient VTE diagnosis only, patients with other indications for oral anticoagulation treatment, patients with previous experience of oral anticoagulation, patients who did not have a prescription for rivaroxaban or warfarin within 7 days of VTE, and patients who redeemed prescriptions for both rivaroxaban and warfarin, or other oral anticoagulants. Primary effectiveness outcome was recurrent VTE and primary safety outcome was major bleeding. We used propensity matching and Cox regression to compare rates of the outcomes with rivaroxaban versus standard treatment. RESULTS: From Dec 9, 2011, to Feb 28, 2016, we identified 29 963 patients with incident VTE. After exclusion, we identified 1734 propensity-matched patients given rivaroxaban (1751 before propensity matching) and 2945 propensity-matched patients given warfarin. The rate of recurrent VTE at 6 months' follow-up was 9·9 incidents per 100 person-years with rivaroxaban versus 13·1 incidents per 100 person-years with warfarin, yielding a hazard ratio (HR) of 0·74 (95% CI 0·56-0·96). The rate of major bleeding was 2·4 per 100 person-years at 6 months in rivaroxaban users versus 2·0 in warfarin users (HR 1·19, 95% CI 0·66-2·13). INTERPRETATION: In this clinical practice setting, rivaroxaban in patients with unprovoked VTE was associated with reduced risk of recurrent VTE compared with standard treatment, without compromising safety. FUNDING: Obel Family Foundation.
引用
- Larsen TB, Skjøth F, Kjældgaard JN, et al. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematol. 2017. PMID: 28411120. doi:10.1016/S2352-3026(17)30054-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。